Greenwich LifeSciences (NASDAQ: GLSI) presented preliminary data from its Phase III FLAMINGO‑01 trial at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, California. The presentation, delivered via a poster and abstract, highlighted a statistically significant increase in delayed‑type hypersensitivity (DTH) reactions among patients treated with GLSI‑100, indicating an expanding immune response to the GP2 peptide.
The company disclosed that more than 1,300 patients have been screened to date, and the non‑HLA‑A02 arm is now fully enrolled with 247–250 participants. The data support the inclusion of both HLA‑A02 and non‑HLA‑A*02 patients in the same randomized arms, potentially broadening the drug’s target population and increasing the statistical power of the trial’s primary endpoint.
In the non‑HLA‑A02 open‑label arm, DTH reactions rose from 5.2 % to 20.4 %, a 290 % increase, with a McNemar p‑value of less than 0.001. This robust immune response suggests that GLSI‑100 may be effective beyond the originally targeted HLA‑A02 subgroup, potentially doubling the addressable market for the product.
The positive immune‑response data reinforce GLSI‑100’s Fast Track designation and support the company’s plan to submit a Biologics License Application (BLA) in the near future. Management noted that the FDA has reviewed plans to expand the trial to include all patient types, a move that could accelerate regulatory approval and broaden commercial opportunities.
Greenwich LifeSciences has raised over $10.5 million through its ATM program in Q1 2026, providing a cash cushion that supports the ongoing Phase III program. The preliminary data are expected to strengthen investor confidence and may influence the timing of a potential FDA submission and the company’s ability to secure additional financing.
Analysts and investors have reacted positively to the data, citing the broader patient applicability and the strong statistical signal as key drivers of optimism. The announcement is expected to influence future interim analyses and regulatory submissions.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.